Health
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple – Mirage News
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the…
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
General19 hours agoVictorian school teacher charged with soliciting child abuse material
-
General10 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Business14 hours agoUp 20% in 2 days, are Codan shares a buy, hold or sell?
-
Business22 hours agoEconomic roundtable or maturity test?